

John A Meyers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2184200/publications.pdf>

Version: 2024-02-01

9
papers

235
citations

1163117

8
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

491
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical assessment of curcumin as a potential therapy for B-CLL. American Journal of Hematology, 2007, 82, 23-30.	4.1	64
2	CD40 Ligand-mediated Activation of the de Novo RelB NF- κ B Synthesis Pathway in Transformed B Cells Promotes Rescue from Apoptosis. Journal of Biological Chemistry, 2007, 282, 17475-17485.	3.4	43
3	Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN- γ and IL-17 secretion by activated human PBMC. Cytokine, 2006, 35, 235-246.	3.2	33
4	Phosphodiesterase 4 Inhibitors Augment Levels of Glucocorticoid Receptor in B Cell Chronic Lymphocytic Leukemia but Not in Normal Circulating Hematopoietic Cells. Clinical Cancer Research, 2007, 13, 4920-4927.	7.0	27
5	Chronic Lymphocytic Leukemia and B and T Cells Differ in Their Response to Cyclic Nucleotide Phosphodiesterase Inhibitors. Journal of Immunology, 2009, 182, 5400-5411.	0.8	27
6	Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. International Immunopharmacology, 2016, 38, 223-232.	3.8	20
7	Inhibition of Type 4 Cyclic Nucleotide Phosphodiesterase Blocks Intracellular TLR Signaling in Chronic Lymphocytic Leukemia and Normal Hematopoietic Cells. Journal of Immunology, 2015, 194, 101-112.	0.8	13
8	PDE4 Inhibitors Augment Glucocorticoid Receptor Levels in B-CLL Cells but Not in T Cells, B Cells, Monocytes or Neutrophils.. Blood, 2006, 108, 2608-2608.	1.4	8
9	PDE4 Inhibitors Enhance DNA Damage-Induced Apoptosis In CLL. Blood, 2010, 116, 2902-2902.	1.4	0